<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">BioData Min</journal-id>
    <journal-id journal-id-type="iso-abbrev">BioData Min</journal-id>
    <journal-title-group>
      <journal-title>BioData Mining</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1756-0381</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7817765</article-id>
    <article-id pub-id-type="publisher-id">234</article-id>
    <article-id pub-id-type="doi">10.1186/s13040-021-00234-1</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Short Report</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Mechanistic modeling of the SARS-CoV-2 disease map</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Rian</surname>
          <given-names>Kinza</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Esteban-Medina</surname>
          <given-names>Marina</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hidalgo</surname>
          <given-names>Marta R.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Çubuk</surname>
          <given-names>Cankut</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Falco</surname>
          <given-names>Matias M.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Loucera</surname>
          <given-names>Carlos</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gunyel</surname>
          <given-names>Devrim</given-names>
        </name>
        <xref ref-type="aff" rid="Aff5">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ostaszewski</surname>
          <given-names>Marek</given-names>
        </name>
        <xref ref-type="aff" rid="Aff5">5</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Peña-Chilet</surname>
          <given-names>María</given-names>
        </name>
        <address>
          <email>maria.pena.chilet.ext@juntadeandalucia.es</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3318-120X</contrib-id>
        <name>
          <surname>Dopazo</surname>
          <given-names>Joaquín</given-names>
        </name>
        <address>
          <email>joaquin.dopazo@juntadeandalucia.es</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff4">4</xref>
        <xref ref-type="aff" rid="Aff6">6</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.411109.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9542 1158</institution-id><institution>Bioinformatics Area, Fundación Progreso y Salud (FPS), </institution><institution>Hospital Virgen del Rocío, </institution></institution-wrap>Sevilla, Spain </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.411109.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9542 1158</institution-id><institution>Computational Systems Medicine, Institute of Biomedicine of Seville (IBIS), </institution><institution>Hospital Virgen del Rocio, </institution></institution-wrap>41013 Sevilla, Spain </aff>
      <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.418274.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0399 600X</institution-id><institution>Bioinformatics and Biostatistics Unit, Centro de Investigación Príncipe Felipe (CIPF), </institution></institution-wrap>46012 Valencia, Spain </aff>
      <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.452372.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1791 1185</institution-id><institution>Bioinformatics in RareDiseases (BiER), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), </institution></institution-wrap>Sevilla, Spain </aff>
      <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.16008.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2295 9843</institution-id><institution>Luxembourg Centre for Systems Biomedicine, </institution><institution>University of Luxembourg, </institution></institution-wrap>L-4367 Belvaux, Luxembourg </aff>
      <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.413448.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9314 1427</institution-id><institution>Functional Genomics Node (INB-ELIXIR-es), </institution></institution-wrap>Sevilla, Spain </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>21</day>
      <month>1</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>21</day>
      <month>1</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2021</year>
    </pub-date>
    <volume>14</volume>
    <elocation-id>5</elocation-id>
    <history>
      <date date-type="received">
        <day>21</day>
        <month>7</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>5</day>
        <month>1</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2021</copyright-statement>
      <license license-type="OpenAccess">
        <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <p id="Par1">Here we present a web interface that implements a comprehensive mechanistic model of the SARS-CoV-2 disease map. In this framework, the detailed activity of the human signaling circuits related to the viral infection, covering from the entry and replication mechanisms to the downstream consequences as inflammation and antigenic response, can be inferred from gene expression experiments. Moreover, the effect of potential interventions, such as knock-downs, or drug effects (currently the system models the effect of more than 8000 DrugBank drugs) can be studied. This freely available tool not only provides an unprecedentedly detailed view of the mechanisms of viral invasion and the consequences in the cell but has also the potential of becoming an invaluable asset in the search for efficient antiviral treatments.</p>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>Mechanistic modeling</kwd>
      <kwd>Signaling pathway</kwd>
      <kwd>Drug discovery</kwd>
      <kwd>COVID-19</kwd>
      <kwd>Systems biology</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003329</institution-id>
            <institution>Ministerio de Economía y Competitividad</institution>
          </institution-wrap>
        </funding-source>
        <award-id>SAF2017-88908-R</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004587</institution-id>
            <institution>Instituto de Salud Carlos III</institution>
          </institution-wrap>
        </funding-source>
        <award-id>PT17/0009/0006</award-id>
        <award-id>COV20/00788</award-id>
        <award-id>ACCI2018/29</award-id>
        <principal-award-recipient>
          <name>
            <surname>Peña-Chilet</surname>
            <given-names>María</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011264</institution-id>
            <institution>FP7 People: Marie-Curie Actions</institution>
          </institution-wrap>
        </funding-source>
        <award-id>813533</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2021</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Introduction</title>
    <p id="Par2">The recent pandemic of COVID-19 (Coronavirus Disease-2019), an emerging respiratory disease caused by the SARS-CoV-2 virus, which spread more efficiently than previous highly pathogenic coronaviruses SARS-CoV and MERS-CoV, has led to a tremendous toll of affected cases and over 500,000 fatalities in more than 200 countries since its first outbreak in late 2019 [<xref ref-type="bibr" rid="CR1">1</xref>]. Precisely due to the rapid transmission of this novel pathogen, no antiviral drugs or vaccines are available for SARS-CoV-2.</p>
    <p id="Par3">Understanding the molecular mechanisms that mediate SARS-CoV-2 infection is key for the rapid development of efficient preventive or therapeutic interventions against the COVID-19. A comprehensive description of such molecular mechanisms is represented in the corresponding disease map, that is, the sub-module of the whole pathway of known human protein functional interactions that summarize details of the disease mechanism and consequently are relevant for understanding the disease [<xref ref-type="bibr" rid="CR2">2</xref>]. The recent availability of a detailed catalog of viral-human protein interactions [<xref ref-type="bibr" rid="CR3">3</xref>] has facilitated the construction of a first version of a map of the human molecular pathways involved in the viral infection and downstream consequences [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
    <p id="Par4">Disease maps are repositories of knowledge of disease-relevant mechanisms that provide qualitative guidance for the interpretation of experimental findings [<xref ref-type="bibr" rid="CR2">2</xref>]. Actually, disease maps are the supporting foundation of different tools able to model the information contained in them in order to provide a detailed quantitative explanation for experimental results [<xref ref-type="bibr" rid="CR5">5</xref>]. In particular, mechanistic models of disease maps are becoming increasingly relevant for genomic data interpretation because they provide a natural link between omics data measurements and cell behavior and outcome [<xref ref-type="bibr" rid="CR6">6</xref>], which ultimately accounts for the phenotype of the infection. The knowledge of these links allows a better understanding of the molecular mechanisms of the viral infection and the responses to drugs. Actually, mechanistic models of human signaling [<xref ref-type="bibr" rid="CR7">7</xref>] or metabolic pathways [<xref ref-type="bibr" rid="CR8">8</xref>] have been successfully used to uncover specific molecular mechanisms behind different cancers [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR11">11</xref>], rare [<xref ref-type="bibr" rid="CR12">12</xref>] and common [<xref ref-type="bibr" rid="CR13">13</xref>] diseases, to reveal mechanisms of action of drugs [<xref ref-type="bibr" rid="CR14">14</xref>], and dissecting them at single cell level [<xref ref-type="bibr" rid="CR15">15</xref>], to suggest personalized treatments [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>] and in other biologically interesting scenarios [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Basically, mechanistic models analyze experimental values in the context of the disease map information, which is used to point out the relevant aspects of the molecular mechanisms behind the experiment. It is important to note that this assessment is made from a systems biology perspective, in the holistic context of the disease map, and considers the functional interactions among the gene products as described in the map. Typically, these experimental values are gene expression transcriptomic data, although other data such as proteomic, phosphoproteomic, genomic [<xref ref-type="bibr" rid="CR20">20</xref>], or even methylomics, can also be used. Interestingly, beyond its usefulness for the functional interpretation of experimental results, the most remarkable property of mechanistic models is that they can be used to predict the effects of interventions (inhibitions, over-activations, drugs, etc., alone or in combinations) over proteins of the map in the condition studied [<xref ref-type="bibr" rid="CR21">21</xref>]. Therefore, this opens the possibility of using these models for exploring new therapeutic options as well [<xref ref-type="bibr" rid="CR22">22</xref>].</p>
  </sec>
  <sec id="Sec2">
    <title>Methods</title>
    <p id="Par5">To construct a first approach to the COVID-19 disease map, the SARS-CoV-2 virus-human interactome was firstly expanded from existing KEGG pathways [<xref ref-type="bibr" rid="CR23">23</xref>] to define regions within the whole set KEGG pathways that potentially account for the molecular mechanism of the viral infection and the downstream consequences. Pathways are composed of individual signaling circuits (sub-pathway that describes the chain of signal transduction that connects a receptor protein to an effector protein) whose functionalities can be described by the UniProt [<xref ref-type="bibr" rid="CR24">24</xref>] functional annotations of their effector nodes [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. It order to restrict the map to those circuits relevant for the COVID-19 disease mechanism, only signaling circuits with at least one UniProt [<xref ref-type="bibr" rid="CR24">24</xref>] function that fit in one of these virus-related categories: 1) Host-virus interaction, 2) inflammatory response, 3) immune activity, 4) antiviral defense, 5) endocytosis were selected to define the COVID-19 disease map. The model presented here is a part of an ongoing more detailed repository of SARS-CoV-2 mechanisms, the COVID-19 Disease Map, in construction by an international community, whose most recent version is available at: 10.17881/covid19-disease-map. In addition to the human version of the COVID-19 map, versions for animal models, like mouse or rat, using the homologous pathways are also provided by the tool [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
    <p id="Par6">The mechanistic model implemented here takes a directed graph (in this case a first version of the COVID-19 map, and in the future new versions as these are released), and extracts from it the collection of signaling circuits that connect receptor nodes to effector nodes. The signal transduction across such circuits, S<sub>n</sub>, is estimated using gene expression values as proxies of protein activity [<xref ref-type="bibr" rid="CR26">26</xref>] using the following recursive equation [<xref ref-type="bibr" rid="CR7">7</xref>]:</p>
    <p id="Par7">
      <disp-formula id="Equ1">
        <label>1</label>
        <alternatives>
          <tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {S}_n={\upsilon}_n\bullet \left(1-\prod \limits_{s_a\in A}\left(1-{s}_a\right)\right)\cdotp \prod \limits_{s_i\in I}\left(1-{s}_i\right) $$\end{document}</tex-math>
          <mml:math id="M2" display="block">
            <mml:msub>
              <mml:mi>S</mml:mi>
              <mml:mi>n</mml:mi>
            </mml:msub>
            <mml:mo>=</mml:mo>
            <mml:msub>
              <mml:mi>υ</mml:mi>
              <mml:mi>n</mml:mi>
            </mml:msub>
            <mml:mo>∙</mml:mo>
            <mml:mfenced close=")" open="(">
              <mml:mrow>
                <mml:mn>1</mml:mn>
                <mml:mo>−</mml:mo>
                <mml:munder>
                  <mml:mo>∏</mml:mo>
                  <mml:mrow>
                    <mml:msub>
                      <mml:mi>s</mml:mi>
                      <mml:mi>a</mml:mi>
                    </mml:msub>
                    <mml:mo>∈</mml:mo>
                    <mml:mi>A</mml:mi>
                  </mml:mrow>
                </mml:munder>
                <mml:mfenced close=")" open="(">
                  <mml:mrow>
                    <mml:mn>1</mml:mn>
                    <mml:mo>−</mml:mo>
                    <mml:msub>
                      <mml:mi>s</mml:mi>
                      <mml:mi>a</mml:mi>
                    </mml:msub>
                  </mml:mrow>
                </mml:mfenced>
              </mml:mrow>
            </mml:mfenced>
            <mml:mo>·</mml:mo>
            <mml:munder>
              <mml:mo>∏</mml:mo>
              <mml:mrow>
                <mml:msub>
                  <mml:mi>s</mml:mi>
                  <mml:mi>i</mml:mi>
                </mml:msub>
                <mml:mo>∈</mml:mo>
                <mml:mi>I</mml:mi>
              </mml:mrow>
            </mml:munder>
            <mml:mfenced close=")" open="(">
              <mml:mrow>
                <mml:mn>1</mml:mn>
                <mml:mo>−</mml:mo>
                <mml:msub>
                  <mml:mi>s</mml:mi>
                  <mml:mi>i</mml:mi>
                </mml:msub>
              </mml:mrow>
            </mml:mfenced>
          </mml:math>
          <graphic xlink:href="13040_2021_234_Article_Equ1.gif" position="anchor"/>
        </alternatives>
      </disp-formula>
    </p>
    <p id="Par8"><italic>S</italic><sub><italic>n</italic></sub> is the signal intensity for the current node <italic>n</italic>, <italic>v</italic><sub><italic>n</italic></sub> is its normalized gene expression value, <italic>A</italic> is the set of activation signals (<italic>s</italic><sub><italic>a</italic></sub>), arriving to the current node from activation edges, <italic>I</italic>is the set of inhibitory signals (<italic>s</italic><sub><italic>i</italic></sub>) arriving to the node from inhibition edges. The <italic>S</italic><sub><italic>n</italic></sub> values of circuits are further used in comparisons to detect increases or decreases in signaling activity (and consequently in the corresponding cell functionality), or to infer the effect of interventions in signaling or the potential resulting phenotype of mutations.</p>
    <sec id="Sec3">
      <title>Implementation</title>
      <p id="Par9">Here, we present the first implementation of a mechanistic model of the SARS-CoV-2 infection in a user-friendly web interface. The model used here implements the <italic>HiPathia</italic> [<xref ref-type="bibr" rid="CR7">7</xref>] algorithm, which has demonstrated to outperform other competing algorithms in a recent benchmarking [<xref ref-type="bibr" rid="CR25">25</xref>]. The mechanistic model implemented in <italic>HiPathia</italic> has been successfully used to understand the disease mechanisms behind different cancers [<xref ref-type="bibr" rid="CR7">7</xref>] and was able to predict cancer vulnerabilities with a high precision [<xref ref-type="bibr" rid="CR9">9</xref>]. The model has been implemented in a user-friendly web application that inputs normalized gene expression values (or similar proteomics or phosphoproteomic values) and can be found at <ext-link ext-link-type="uri" xlink:href="http://hipathia.babelomics.org/covid19/">http://hipathia.babelomics.org/covid19/</ext-link>. As an example, we carried out some analyses that involve a case-control differential signaling analysis using a recently published gene expression experiment [<xref ref-type="bibr" rid="CR27">27</xref>] with human lung cell lines infected with SARS-CoV-2 (GEO id: GSE147507, the dataset GSE147507_RawReadCounts_Human.ts). The infected cells showed a differential activation pattern in circuits related to virus entrance to cell, activation of immune, inflammatory and other virus-triggered responses (see Fig. <xref rid="Fig1" ref-type="fig">1</xref>a and Table <xref rid="Tab1" ref-type="table">1</xref> for a detailed list of differentially activated signaling circuits and Table <xref rid="Tab2" ref-type="table">2</xref> for detail on the differentially activated cell functionalities). Interestingly, several of the deregulated pathways include <italic>TNF</italic>, a target gene of chloroquine, one of the drugs with promising results against COVID-19 [<xref ref-type="bibr" rid="CR28">28</xref>]. Moreover, NF-kB signaling pathway has been highlighted in several studies as one of the main pathways responsible for COVID-19 progression [<xref ref-type="bibr" rid="CR29">29</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref> B). Figure <xref rid="Fig1" ref-type="fig">1</xref>c depicts the heathmap of signaling activity profiles that discriminate the two classes of samples (cases and controls) compared. The results found are consistent with those of previous analyses with the same data, where a modest but generalized response of mechanisms related to immune response and inflammatory processes, such as response to chemokine and cytokines, virus defense-related processes, and other general functions of cell like apoptosis or cell differentiation was demonstrated [<xref ref-type="bibr" rid="CR27">27</xref>]. Interestingly, the processes highlighted by the authors are response to chemokines and interferon-related signaling pathways. Both processes are highly associated with pathways in whose circuits our model detect significant deregulations (see Table <xref rid="Tab1" ref-type="table">1</xref>), such as Toll-like and TNF signaling pathways. The relation between chemokines, interferon and Toll-like signaling is well-known [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], moreover, interferon is a key player in TNF signaling pathway [<xref ref-type="bibr" rid="CR32">32</xref>], and both signaling pathways are interrelated. Beyong the pure interpretation of the results, another novel and very useful option of the implementation of the model is the <italic>Perturbation effect</italic>. It allows estimating the effect of interventions (inhibitions or overexpression) across the signaling circuits of the model in a given condition. Moreover, the effect of more than 8000 targeted drugs from DrugBank can be predicted by selecting them, individually or in combinations. Figure <xref rid="Fig1" ref-type="fig">1</xref>d shows and example of the <italic>Perturbation effect</italic> option in which the impact of Siltuximab, a drug in study in patients with COVID-19 respiratory failure [<xref ref-type="bibr" rid="CR33">33</xref>] which targets protein <italic>IL6</italic>, is simulated. Individual gene expression levels in each node are represented in shades of grayish green. Figure <xref rid="Fig1" ref-type="fig">1</xref>e, shows an example of the <italic>Variant interpreter</italic> option simulating the effect of a loss of function mutation in <italic>NFKBIA</italic> gene product over lung tissue pathway activity. One of the affected circuits in TNF signaling pathway is shown. Mean values of gene expression levels in each node are represented in shades of grayish green. A detailed description of the usage of the tool can be found in the accompanying help and tutorial.
<fig id="Fig1"><label>Fig. 1</label><caption><p><bold>a</bold> Activation pattern of NF-KB pathway in lung cell lines infected with SARS-CoV-2. <bold>b</bold> Detail of NF-KB pathway’s circuit with TNF as effector protein. <bold>c</bold> Heatmap representing activation values of all the circuits in COVID-19 disease map (left) and a representation of a Principal Component Analysis based on signaling profiles of the samples that clearly segregates the two conditions studied: controls are represented in dark blue and cases in purple (right). <bold>d</bold> An example of the <italic>Perturbation effect</italic> option simulating the effect of Siltuximab (targeting <italic>IL6</italic> protein<italic>)</italic> in Toll-like signaling pathway. Individual gene expression levels in each node are represented green scale. <bold>e</bold> An example of the <italic>Variant interpreter</italic> option simulating the effect of a loss of function mutation in <italic>NFKBIA</italic> protein over lung tissue pathway activity in the TNF signaling pathway. Mean values of gene expression levels in each node are represented in green scale</p></caption><graphic xlink:href="13040_2021_234_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Circuits from CoV-Hipathia differentially activated in lung cell lines infected with SARS-CoV-2</p></caption><table frame="hsides" rules="groups"><thead><tr><th>KEGG pathway: effector gene/s</th><th>UP/ DOWN</th><th>statistic</th><th><bold><italic>p</italic></bold>-value<sup><bold>a</bold></sup></th><th>FDR<sup><bold>b</bold></sup></th><th>FC<sup><bold>c</bold></sup></th><th>log FC</th></tr></thead><tbody><tr><td>MAPK signaling pathway: NLK</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.098</td><td>0.135</td></tr><tr><td>MAPK signaling pathway: STK3</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.209</td><td>0.274</td></tr><tr><td>MAPK signaling pathway: ECSIT, TRAF6</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.182</td><td>0.241</td></tr><tr><td>Ras signaling pathway: REL</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.074</td><td>0.103</td></tr><tr><td>Ras signaling pathway: MLLT4</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.049</td><td>0.069</td></tr><tr><td>NF-kappa B signaling pathway: CFLAR</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.212</td><td>0.278</td></tr><tr><td>NF-kappa B signaling pathway: BIRC2</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.261</td><td>0.335</td></tr><tr><td>NF-kappa B signaling pathway: XIAP</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.176</td><td>0.234</td></tr><tr><td>NF-kappa B signaling pathway: BCL2L1</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.193</td><td>0.254</td></tr><tr><td>NF-kappa B signaling pathway: GADD45B</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.179</td><td>0.238</td></tr><tr><td>NF-kappa B signaling pathway: BCL2A1</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.570</td><td>0.651</td></tr><tr><td>NF-kappa B signaling pathway: NFKB2</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.225</td><td>0.293</td></tr><tr><td>NF-kappa B signaling pathway: CXCL8</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.185</td><td>0.245</td></tr><tr><td>NF-kappa B signaling pathway: IL1B</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.341</td><td>0.424</td></tr><tr><td>NF-kappa B signaling pathway: TNFAIP3</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.311</td><td>0.390</td></tr><tr><td>NF-kappa B signaling pathway: NFKBIA</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.254</td><td>0.327</td></tr><tr><td>NF-kappa B signaling pathway: PTGS2</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.267</td><td>0.341</td></tr><tr><td>NF-kappa B signaling pathway: CXCL2</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.335</td><td>0.417</td></tr><tr><td>NF-kappa B signaling pathway: IKBKG, CHUK, IKBKB</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.110</td><td>0.151</td></tr><tr><td>NF-kappa B signaling pathway: BCL2L1</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.098</td><td>0.135</td></tr><tr><td>NF-kappa B signaling pathway: BCL2A1</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.448</td><td>0.534</td></tr><tr><td>HIF-1 signaling pathway: TIMP1</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.051</td><td>0.072</td></tr><tr><td>HIF-1 signaling pathway: TIMP1</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.051</td><td>0.072</td></tr><tr><td>HIF-1 signaling pathway: EDN1</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.121</td><td>0.164</td></tr><tr><td>HIF-1 signaling pathway: NOS2</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.585</td><td>0.664</td></tr><tr><td>HIF-1 signaling pathway: PDK1</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.037</td><td>0.052</td></tr><tr><td>HIF-1 signaling pathway: PGK1</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.048</td><td>0.068</td></tr><tr><td>HIF-1 signaling pathway: LDHA</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.047</td><td>0.066</td></tr><tr><td>mTOR signaling pathway: VEGFA</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.059</td><td>0.083</td></tr><tr><td>mTOR signaling pathway: TSC1</td><td>DOWN</td><td>−2.882</td><td>2.16E-03</td><td>0.023</td><td>0.946</td><td>−0.080</td></tr><tr><td>PI3K-Akt signaling pathway: BCL2L11</td><td>DOWN</td><td>−2.882</td><td>2.16E-03</td><td>0.023</td><td>0.918</td><td>−0.123</td></tr><tr><td>Apoptosis: FADD, TRADD</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.118</td><td>0.161</td></tr><tr><td>Apoptosis: IRAK3, MYD88</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.167</td><td>0.223</td></tr><tr><td>Toll-like receptor signaling pathway: CXCL10</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.518</td><td>0.602</td></tr><tr><td>Toll-like receptor signaling pathway: IFNA1</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.486</td><td>0.572</td></tr><tr><td>Toll-like receptor signaling pathway: IL1B</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.172</td><td>0.229</td></tr><tr><td>Toll-like receptor signaling pathway: IL6</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.526</td><td>0.610</td></tr><tr><td>RIG-I-like receptor signaling pathway: MAPK14</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.214</td><td>0.280</td></tr><tr><td>RIG-I-like receptor signaling pathway: MAVS, TMEM173</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.204</td><td>0.268</td></tr><tr><td>RIG-I-like receptor signaling pathway: IRF7</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.023</td><td>1.540</td><td>0.623</td></tr><tr><td>Ras signaling pathway: MAPK8</td><td>UP</td><td>2.722</td><td>4.33E-03</td><td>0.035</td><td>1.043</td><td>0.061</td></tr><tr><td>NF-kappa B signaling pathway: TRAF1</td><td>UP</td><td>2.722</td><td>4.33E-03</td><td>0.035</td><td>1.193</td><td>0.254</td></tr><tr><td>NF-kappa B signaling pathway: TNF</td><td>UP</td><td>2.722</td><td>4.33E-03</td><td>0.035</td><td>1.639</td><td>0.713</td></tr><tr><td>HIF-1 signaling pathway: TFRC</td><td>UP</td><td>2.722</td><td>4.33E-03</td><td>0.035</td><td>1.049</td><td>0.068</td></tr><tr><td>Sphingolipid signaling pathway: SMPD2</td><td>UP</td><td>2.722</td><td>4.33E-03</td><td>0.035</td><td>1.388</td><td>0.473</td></tr><tr><td>Apoptosis: FADD, TRADD</td><td>UP</td><td>2.722</td><td>4.33E-03</td><td>0.035</td><td>1.358</td><td>0.442</td></tr><tr><td>Apoptosis: TRAF2, RIPK1, TRADD</td><td>UP</td><td>2.722</td><td>4.33E-03</td><td>0.035</td><td>1.358</td><td>0.442</td></tr><tr><td>Toll-like receptor signaling pathway: TNF</td><td>UP</td><td>2.722</td><td>4.33E-03</td><td>0.035</td><td>1.434</td><td>0.520</td></tr><tr><td>TNF signaling pathway: CASP7</td><td>UP</td><td>2.722</td><td>4.33E-03</td><td>0.035</td><td>1.388</td><td>0.473</td></tr><tr><td>TNF signaling pathway: CASP3</td><td>UP</td><td>2.722</td><td>4.33E-03</td><td>0.035</td><td>1.371</td><td>0.455</td></tr><tr><td>TNF signaling pathway: BAG4</td><td>UP</td><td>2.722</td><td>4.33E-03</td><td>0.035</td><td>1.391</td><td>0.476</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> P-value is calculated using Wilcoxon test</p><p><sup>b</sup> FDR refers to p-value adjusted for multiple comparisons using Benjamini and Hochberg method</p><p><sup>c</sup> FC means Fold Change</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Functions from CoV-Hipathia differentially activated in lung cell lines infected with SARS-CoV-2</p></caption><table frame="hsides" rules="groups"><thead><tr><th>UniProt function</th><th>UP/DOWN</th><th>statistic</th><th>p-value<sup><bold>a</bold></sup></th><th>FDR<sup><bold>b</bold></sup></th><th>FC<sup><bold>c</bold></sup></th><th>logFC</th></tr></thead><tbody><tr><td>Innate immunity</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.018</td><td>1.048</td><td>0.067</td></tr><tr><td>Immunity</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.018</td><td>1.019</td><td>0.028</td></tr><tr><td>Inflammatory response</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.018</td><td>1.028</td><td>0.041</td></tr><tr><td>Antiviral defense</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.018</td><td>1.192</td><td>0.253</td></tr><tr><td>Pyrogen</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.018</td><td>1.177</td><td>0.235</td></tr><tr><td>Prostaglandin biosynthesis</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.018</td><td>1.267</td><td>0.341</td></tr><tr><td>Prostaglandin metabolism</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.018</td><td>1.267</td><td>0.341</td></tr><tr><td>Fatty acid biosynthesis</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.018</td><td>1.266</td><td>0.341</td></tr><tr><td>Lipid biosynthesis</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.018</td><td>1.266</td><td>0.341</td></tr><tr><td>Acute phase</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.018</td><td>1.526</td><td>0.610</td></tr><tr><td>Osteogenesis</td><td>UP</td><td>2.882</td><td>2.16E-03</td><td>0.018</td><td>1.181</td><td>0.241</td></tr><tr><td>Autophagy</td><td>DOWN</td><td>−2.722</td><td>4.33E-03</td><td>0.028</td><td>0.976</td><td>−0.035</td></tr><tr><td>Translation regulation</td><td>UP</td><td>2.722</td><td>4.33E-03</td><td>0.028</td><td>1.015</td><td>0.022</td></tr><tr><td>Sphingolipid metabolism</td><td>UP</td><td>2.722</td><td>4.33E-03</td><td>0.028</td><td>1.388</td><td>0.473</td></tr><tr><td>Necrosis</td><td>UP</td><td>2.562</td><td>8.66E-03</td><td>0.046</td><td>1.009</td><td>0.013</td></tr><tr><td>Fibrinolysis</td><td>UP</td><td>2.562</td><td>8.66E-03</td><td>0.046</td><td>1.103</td><td>0.141</td></tr><tr><td>Plasminogen activation</td><td>UP</td><td>2.562</td><td>8.66E-03</td><td>0.046</td><td>1.072</td><td>0.101</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> P-value is calculated using Wilcoxon test</p><p><sup>b</sup> FDR refers to p-value adjusted for multiple comparisons using Benjamini and Hochberg method</p><p><sup>c</sup> FC means Fold Change</p></table-wrap-foot></table-wrap></p>
      <p id="Par10">Despite the limitations due to the few samples available, the results of the example clearly show the usefulness of this tool for modelling the repertoire of cell responses triggered by SARS-CoV-2, and the enormous potential that it has for future COVID-19 research and discovery of therapeutic interventions. Moreover, in spite of its short life CoV-Hipathia has already been quoted among other useful web tools to fight the COVID-19 pandemic [<xref ref-type="bibr" rid="CR34">34</xref>] .</p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher’s Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
    <fn>
      <p>Kinza Rian and Marina Esteban-Medina contributed equally to this work.</p>
    </fn>
  </fn-group>
  <ack>
    <title>Acknowledgements</title>
    <p>Not applicable.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Authors’ contributions</title>
    <p>KR developed the mechanistic modeling software, MEM carried out the mechanistic modeling analysis, MRL developed the algorithm, CL implemented the predictors in the software, DG and MO developed the COVID-10 disease map, JD and MPC conceived the work and wrote the paper. All authors read and approved the final manuscript.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>This work is supported by grants SAF2017–88908-R from the Spanish Ministry of Economy and Competitiveness, PT17/0009/0006, ACCI2018/29 from CIBER-ISCIII and COV20/00788 from the ISCIII, co-funded with European Regional Development Funds (ERDF), the grant “Large-scale drug repurposing in rare diseases by genomic Big Data analysis with machine learning methods” from the Fundación BBVA (G999088Q), as well as H2020 Programme of the European Union grants Marie Curie Innovative Training Network “Machine Learning Frontiers in Precision Medicine” (MLFPM) (GA 813533).</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Availability of data and materials</title>
    <p>The dataset used during the current study is available in the GEO database, [<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147507">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147507</ext-link>], the COVID-19 Disease Map used here is available [10.5281/zenodo.3935733], and new versions will be made publicly available here [10.17881/covid19-disease-map].</p>
    <p>This tool freely available at: <ext-link ext-link-type="uri" xlink:href="http://hipathia.babelomics.org/covid19/">http://hipathia.babelomics.org/covid19/</ext-link></p>
  </notes>
  <notes id="FPar1">
    <title>Ethics approval and consent to participate</title>
    <p id="Par11">Not applicable.</p>
  </notes>
  <notes id="FPar2">
    <title>Consent for publication</title>
    <p id="Par12">Not applicable.</p>
  </notes>
  <notes id="FPar3" notes-type="COI-statement">
    <title>Competing interests</title>
    <p id="Par13">The authors declare that they have no competing interests.</p>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Horby</surname>
            <given-names>PW</given-names>
          </name>
          <name>
            <surname>Hayden</surname>
            <given-names>FG</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>GF</given-names>
          </name>
        </person-group>
        <article-title>A novel coronavirus outbreak of global health concern</article-title>
        <source>Lancet</source>
        <year>2020</year>
        <volume>395</volume>
        <issue>10223</issue>
        <fpage>470</fpage>
        <lpage>473</lpage>
        <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30185-9</pub-id>
        <pub-id pub-id-type="pmid">31986257</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ostaszewski</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gebel</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kuperstein</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Mazein</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Zinovyev</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Dogrusoz</surname>
            <given-names>U</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Community-driven roadmap for integrated disease maps</article-title>
        <source>Briefings Bioinformatics</source>
        <year>2019</year>
        <volume>20</volume>
        <issue>2</issue>
        <fpage>659</fpage>
        <lpage>670</lpage>
        <pub-id pub-id-type="doi">10.1093/bib/bby024</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gordon</surname>
            <given-names>DE</given-names>
          </name>
          <name>
            <surname>Jang</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Bouhaddou</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Obernier</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>White</surname>
            <given-names>KM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</article-title>
        <source>Nature</source>
        <year>2020</year>
        <volume>583</volume>
        <issue>7816</issue>
        <fpage>459</fpage>
        <lpage>468</lpage>
        <pub-id pub-id-type="doi">10.1038/s41586-020-2286-9</pub-id>
        <pub-id pub-id-type="pmid">32353859</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ostaszewski</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Mazein</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Gillespie</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Kuperstein</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Niarakis</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hermjakob</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms</article-title>
        <source>Scientific Data</source>
        <year>2020</year>
        <volume>7</volume>
        <issue>1</issue>
        <fpage>136</fpage>
        <pub-id pub-id-type="doi">10.1038/s41597-020-0477-8</pub-id>
        <pub-id pub-id-type="pmid">32371892</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mazein</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ostaszewski</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kuperstein</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Watterson</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Le Novère</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Lefaudeux</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Systems medicine disease maps: community-driven comprehensive representation of disease mechanisms</article-title>
        <source>npj Systems Biol Applications</source>
        <year>2018</year>
        <volume>4</volume>
        <issue>1</issue>
        <fpage>21</fpage>
        <pub-id pub-id-type="doi">10.1038/s41540-018-0059-y</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>MK</given-names>
          </name>
          <name>
            <surname>Kramer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dutkowski</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Srivas</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Licon</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kreisberg</surname>
            <given-names>JF</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Translation of genotype to phenotype by a hierarchy of cell subsystems</article-title>
        <source>Cell Systems</source>
        <year>2016</year>
        <volume>2</volume>
        <issue>2</issue>
        <fpage>77</fpage>
        <lpage>88</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cels.2016.02.003</pub-id>
        <pub-id pub-id-type="pmid">26949740</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hidalgo</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Cubuk</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Amadoz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Salavert</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Carbonell-Caballero</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Dopazo</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes</article-title>
        <source>Oncotarget</source>
        <year>2017</year>
        <volume>8</volume>
        <issue>3</issue>
        <fpage>5160</fpage>
        <lpage>5178</lpage>
        <pub-id pub-id-type="doi">10.18632/oncotarget.14107</pub-id>
        <pub-id pub-id-type="pmid">28042959</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Çubuk</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Hidalgo</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Amadoz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rian</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Salavert</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Pujana</surname>
            <given-names>MA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Differential metabolic activity and discovery of therapeutic targets using summarized metabolic pathway models</article-title>
        <source>NPJ Systems Biology</source>
        <year>2019</year>
        <volume>5</volume>
        <issue>1</issue>
        <fpage>7</fpage>
        <pub-id pub-id-type="doi">10.1038/s41540-019-0087-2</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cubuk</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Hidalgo</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Amadoz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pujana</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Mateo</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Herranz</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene expression integration into pathway modules reveals a pan-cancer metabolic landscape</article-title>
        <source>Cancer Research</source>
        <year>2018</year>
        <volume>78</volume>
        <issue>21</issue>
        <fpage>6059</fpage>
        <lpage>6072</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-2705</pub-id>
        <pub-id pub-id-type="pmid">30135189</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fey</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Halasz</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dreidax</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kennedy</surname>
            <given-names>SP</given-names>
          </name>
          <name>
            <surname>Hastings</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Rauch</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients</article-title>
        <source>Sci Signal</source>
        <year>2015</year>
        <volume>8</volume>
        <issue>408</issue>
        <fpage>ra130</fpage>
        <pub-id pub-id-type="doi">10.1126/scisignal.aab0990</pub-id>
        <pub-id pub-id-type="pmid">26696630</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hidalgo</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Amadoz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cubuk</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Carbonell-Caballero</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Dopazo</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Models of cell signaling uncover molecular mechanisms of high-risk neuroblastoma and predict disease outcome</article-title>
        <source>Biology Direct.</source>
        <year>2018</year>
        <volume>13</volume>
        <issue>1</issue>
        <fpage>16</fpage>
        <pub-id pub-id-type="doi">10.1186/s13062-018-0219-4</pub-id>
        <pub-id pub-id-type="pmid">30134948</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chacón-Solano</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>León</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Díaz</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>García-García</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>García</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Escámez</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Fibroblasts activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses</article-title>
        <source>J British Journal of Dermatology</source>
        <year>2019</year>
        <volume>181</volume>
        <issue>3</issue>
        <fpage>512</fpage>
        <lpage>522</lpage>
        <pub-id pub-id-type="doi">10.1111/bjd.17698</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Peña-Chilet</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Esteban-Medina</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Falco</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Rian</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Hidalgo</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Loucera</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Using mechanistic models for the clinical interpretation of complex genomic variation</article-title>
        <source>Scientific Reports</source>
        <year>2019</year>
        <volume>9</volume>
        <issue>1</issue>
        <fpage>1</fpage>
        <lpage>12</lpage>
        <pub-id pub-id-type="doi">10.1038/s41598-019-55454-7</pub-id>
        <pub-id pub-id-type="pmid">30626917</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Amadoz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Sebastian-Leon</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Vidal</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Salavert</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Dopazo</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity</article-title>
        <source>Scientific Reports</source>
        <year>2015</year>
        <volume>5</volume>
        <fpage>18494</fpage>
        <pub-id pub-id-type="doi">10.1038/srep18494</pub-id>
        <pub-id pub-id-type="pmid">26678097</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <mixed-citation publication-type="other">Falco MM, Peña-Chilet M, Loucera C, Hidalgo MR, Dopazo J. Mechanistic models of signaling pathways deconvolute the glioblastoma single-cell functional landscape. NAR Cancer. 2020;2(2):zcaa011.</mixed-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <mixed-citation publication-type="other">Saez-Rodriguez J, Blüthgen N. Personalized signaling models for personalized treatments. Molecular Systems Biology. 2020;16(1):e9042.</mixed-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <mixed-citation publication-type="other">Hastings JF, O'Donnell Y, Fey D, Croucher DR. Applications of personalised signalling network models in precision oncology. Pharmacology Therapeutics. 2020;212:107555.</mixed-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Razzoli</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Frontini</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Gurney</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mondini</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Cubuk</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Katz</surname>
            <given-names>LS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Stress-induced activation of brown adipose tissue prevents obesity in conditions of low adaptive thermogenesis</article-title>
        <source>Molecular Metabolism</source>
        <year>2016</year>
        <volume>5</volume>
        <issue>1</issue>
        <fpage>19</fpage>
        <lpage>33</lpage>
        <pub-id pub-id-type="doi">10.1016/j.molmet.2015.10.005</pub-id>
        <pub-id pub-id-type="pmid">26844204</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <mixed-citation publication-type="other">Ferreira PG, Muñoz-Aguirre M, Reverter F, CPS G, Sousa A, Amadoz A, et al. The effects of death and post-mortem cold ischemia on human tissue transcriptomes. Nature Communications. 2018, 9(1):490.</mixed-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hernansaiz-Ballesteros</surname>
            <given-names>RD</given-names>
          </name>
          <name>
            <surname>Salavert</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Sebastian-Leon</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Aleman</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Medina</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Dopazo</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Assessing the impact of mutations found in next generation sequencing data over human signaling pathways</article-title>
        <source>Nucleic Acids Res</source>
        <year>2015</year>
        <volume>43</volume>
        <issue>W1</issue>
        <fpage>W270</fpage>
        <lpage>W275</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkv349</pub-id>
        <pub-id pub-id-type="pmid">25883139</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <mixed-citation publication-type="other">Salavert F, Hidalgo MR, Amadoz A, Cubuk C, Medina I, Crespo D, et al. Actionable pathways: interactive discovery of therapeutic targets using signaling pathway models, Nucleic Acids Res. 2016;44(W1):W212–6.</mixed-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Esteban-Medina</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Peña-Chilet</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Loucera</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Dopazo</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Exploring the druggable space around the Fanconi anemia pathway using machine learning and mechanistic models</article-title>
        <source>BMC Bioinformatics</source>
        <year>2019</year>
        <volume>20</volume>
        <issue>1</issue>
        <fpage>370</fpage>
        <pub-id pub-id-type="doi">10.1186/s12859-019-2969-0</pub-id>
        <pub-id pub-id-type="pmid">31266445</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kanehisa</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sato</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kawashima</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Furumichi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tanabe</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>KEGG as a reference resource for gene and protein annotation</article-title>
        <source>Nucleic Acids Research</source>
        <year>2015</year>
        <volume>44</volume>
        <issue>D1</issue>
        <fpage>D457</fpage>
        <lpage>DD62</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkv1070</pub-id>
        <pub-id pub-id-type="pmid">26476454</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <mixed-citation publication-type="other">UniProt_Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic acids research. 2018;47(D1):D506–D15.</mixed-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Amadoz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hidalgo</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Çubuk</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Carbonell-Caballero</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Dopazo</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>A comparison of mechanistic signaling pathway activity analysis methods</article-title>
        <source>Briefings Bioinformatics</source>
        <year>2019</year>
        <volume>20</volume>
        <issue>5</issue>
        <fpage>1655</fpage>
        <lpage>1668</lpage>
        <pub-id pub-id-type="doi">10.1093/bib/bby040</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mitsos</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Melas</surname>
            <given-names>IN</given-names>
          </name>
          <name>
            <surname>Siminelakis</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Chairakaki</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Saez-Rodriguez</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Alexopoulos</surname>
            <given-names>LG</given-names>
          </name>
        </person-group>
        <article-title>Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data</article-title>
        <source>PLoS Comput Biol</source>
        <year>2009</year>
        <volume>5</volume>
        <issue>12</issue>
        <fpage>e1000591</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pcbi.1000591</pub-id>
        <pub-id pub-id-type="pmid">19997482</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Blanco-Melo</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Nilsson-Payant</surname>
            <given-names>BE</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>WC</given-names>
          </name>
          <name>
            <surname>Uhl</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hoagland</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Møller</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19</article-title>
        <source>Cell</source>
        <year>2020</year>
        <volume>181</volume>
        <issue>5</issue>
        <fpage>1036</fpage>
        <lpage>1045</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2020.04.026</pub-id>
        <pub-id pub-id-type="pmid">32416070</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <mixed-citation publication-type="other">Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends. 2020;14:72-73.</mixed-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Martin</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2</article-title>
        <source>Cell Discovery</source>
        <year>2020</year>
        <volume>6</volume>
        <issue>1</issue>
        <fpage>1</fpage>
        <lpage>18</lpage>
        <?supplied-pmid 33402673?>
        <pub-id pub-id-type="pmid">33402673</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tsuboi</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Yoshikai</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Matsuo</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kikuchi</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Iwami</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Nagai</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Roles of toll-like receptors in C-C chemokine production by renal tubular epithelial cells</article-title>
        <source>J Immunol.</source>
        <year>2002</year>
        <volume>169</volume>
        <issue>4</issue>
        <fpage>2026</fpage>
        <lpage>2033</lpage>
        <pub-id pub-id-type="doi">10.4049/jimmunol.169.4.2026</pub-id>
        <pub-id pub-id-type="pmid">12165529</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Perkins</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Vogel</surname>
            <given-names>SN</given-names>
          </name>
        </person-group>
        <article-title>Space and time: New considerations about the relationship between Toll-like receptors (TLRs) and type I interferons (IFNs)</article-title>
        <source>Cytokine</source>
        <year>2015</year>
        <volume>74</volume>
        <issue>2</issue>
        <fpage>171</fpage>
        <lpage>174</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cyto.2015.03.001</pub-id>
        <pub-id pub-id-type="pmid">25819430</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yarilina</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ivashkiv</surname>
            <given-names>LB</given-names>
          </name>
        </person-group>
        <article-title>Type I interferon: a new player in TNF signaling</article-title>
        <source>Curr Dir Autoimmun</source>
        <year>2010</year>
        <volume>11</volume>
        <fpage>94</fpage>
        <lpage>104</lpage>
        <pub-id pub-id-type="doi">10.1159/000289199</pub-id>
        <pub-id pub-id-type="pmid">20173389</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <mixed-citation publication-type="other">Gritti G, Raimondi F, Ripamonti D, Riva I, Landi F, Alborghetti L, et al. IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study. medRxiv. 2020:2020.04.01.20048561.</mixed-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <mixed-citation publication-type="other">Mercatelli D, Holding AN, Giorgi FM. Web tools to fight pandemics: the COVID-19 experience. Brief Bioinform. 2020:bbaa261. 10.1093/bib/bbaa261. Epub ahead of print.</mixed-citation>
    </ref>
  </ref-list>
</back>
